Literature DB >> 10432401

Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome.

K Liang1, N D Vaziri.   

Abstract

BACKGROUND: Nephrotic syndrome (NS) is a prototype of acquired hypercholesterolemia. Hepatic synthesis and removal of cholesterol play major roles in the regulation of plasma concentration of this sterol. Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particles are the primary vehicles for cholesterol transport to the liver. We have recently demonstrated that NS results in acquired hepatic LDL receptor deficiency in rats. This study was undertaken to determine the effect of NS on hepatic expression of the newly discovered, long-sought HDL receptor.
METHODS: Hepatic HDL receptor and apolipoprotein A-I (apo A-I) expressions were studied in rats with puromycin-induced NS. The results were compared with those obtained in placebo-treated, normal controls.
RESULTS: The NS group exhibited a marked reduction in hepatic tissue HDL receptor protein abundance when compared with the control group. In contrast, hepatic HDL receptor mRNA abundance in the NS group was similar to that of the control group. As expected, the NS group showed a marked increase in hepatic apo A-I mRNA abundance.
CONCLUSIONS: The study explored the effect of experimental NS on hepatic HDL receptor expression, and the results revealed a marked down-regulation of HDL receptor in rats with NS. In contrast, hepatic expression of Apo A-I, the principal protein constituent of HDL, was markedly increased in NS rats. The HDL receptor deficiency shown here can potentially limit the efficiency of HDL as the primary vehicle for reverse cholesterol transport in NS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10432401     DOI: 10.1046/j.1523-1755.1999.00585.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  15 in total

1.  The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.

Authors:  Mary E Haas; Amy E Levenson; Xiaowei Sun; Wan-Hui Liao; Joseph M Rutkowski; Sarah D de Ferranti; Valerie A Schumacher; Philipp E Scherer; David J Salant; Sudha B Biddinger
Journal:  Circulation       Date:  2016-07-05       Impact factor: 29.690

Review 2.  Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.

Authors:  Nosratola D Vaziri
Journal:  Kidney Int       Date:  2016-04-26       Impact factor: 10.612

Review 3.  Statins in the management of dyslipidemia associated with chronic kidney disease.

Authors:  Murray Epstein; Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

Review 4.  Causes of dysregulation of lipid metabolism in chronic renal failure.

Authors:  Nosratola D Vaziri
Journal:  Semin Dial       Date:  2009 Nov-Dec       Impact factor: 3.455

Review 5.  High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.

Authors:  Georges Khoueiry; Mokhtar Abdallah; Faisal Saiful; Nidal Abi Rafeh; Muhammad Raza; Tariq Bhat; Suzanne El-Sayegh; Kamyar Kalantar-Zadeh; James Lafferty
Journal:  Int Urol Nephrol       Date:  2013-02-27       Impact factor: 2.370

Review 6.  Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.

Authors:  Nosratola D Vaziri; Keith C Norris
Journal:  Blood Purif       Date:  2013-01-22       Impact factor: 2.614

7.  Reverse cholesterol transport pathway in experimental chronic renal failure.

Authors:  Hamid Moradi; Jun Yuan; Zhemin Ni; Keith Norris; Nosratola D Vaziri
Journal:  Am J Nephrol       Date:  2009-03-24       Impact factor: 3.754

8.  Expression profiling of hepatic genes associated with lipid metabolism in nephrotic rats.

Authors:  Yunfeng Zhou; Xiaoyan Zhang; Lihong Chen; Jing Wu; Huaixin Dang; Mingfen Wei; Yanbo Fan; Yahua Zhang; Yi Zhu; Nanping Wang; Matthew D Breyer; Youfei Guan
Journal:  Am J Physiol Renal Physiol       Date:  2008-07-09

9.  ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction.

Authors:  Mahmut Ilker Yilmaz; Alper Sonmez; Mutlu Saglam; Abdul R Qureshi; Juan Jesus Carrero; Kayser Caglar; Tayfun Eyileten; Erdinc Cakir; Yusuf Oguz; Abdulgaffar Vural; Mujdat Yenicesu; Bengt Lindholm; Peter Stenvinkel; Jonas Axelsson
Journal:  J Am Soc Nephrol       Date:  2008-01-16       Impact factor: 10.121

Review 10.  HDL abnormalities in nephrotic syndrome and chronic kidney disease.

Authors:  Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2015-11-16       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.